AstraZeneca launches Brilinta adherence effort

Share this article:
AstraZeneca launched a new adherence program for its antiplatelet Brilinta, dubbed Complete the Course.

Enrollees will get multichannel support services, including “Access My Brilinta,” which offers “time-saving prescription access and affordability information” to patients and providers alike, said the company.

The program, said AstraZeneca, was designed to address patient preference for how they receive medical info as they transition from hospital to home. The company conducted a patient survey finding that patients with Acute Coronary Syndrome want more info about their medications across multiple channels.

“With over one million people diagnosed with ACS every year, there is an ever increasing need for additional tools and resources that can help patients and their caregivers learn about and understand ACS,” said AstraZeneca VP for global medical affairs James Ferguson, MD. “These materials may help patients maintain their medication regimen.”

The program is built around key transition points, dubbed Learning, Reinforcement and Re-education.

Brilinta was approved in the US in July of 2011 and competes with Plavix.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...